Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Harbin Pharmaceutical Group markets over 130 pharmaceutical products across a broad spectrum of therapeutic areas. At least three biologic drugs (recombinant human erythropoietin, recombinant granulocyte-macrophage colony-stimulating factor, interferon) have regulatory approval in China for indications including anemia. The company maintains ongoing clinical trials and new product developments in chronic diseases, oncology, cardiovascular and other areas.[2][3][9]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Harbin Oubang Pharmaceutical.